Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Hepcidin is the master regulator of systemic iron homeostasis, facilitating iron balance by controlling intestinal iron absorption and recycling. Hepcidin levels are suppressed when erythropoiesis is stimulated, for example following acute blood loss, appropriately enhancing cellular iron export to the plasma to support production of new red blood cells. However, persistent increased and ineffective erythropoiesis, for example in thalassemia, results in sustained elevations in iron absorption, which cause iron overload with associated organ toxicities. The ligands, receptors, and canonical pathways by which iron loading and inflammation upregulate hepcidin expression have been largely established. However, although several mechanisms have been proposed, the means by which erythropoiesis causes hepcidin suppression have been unclear. The erythroid-derived hormone erythroferrone appears to be a convincing candidate for the link between increased erythropoiesis and hepcidin suppression. If confirmed to be clinically and physiologically relevant in humans, potentiation or inhibition of erythroferrone activity could be a crucial pharmaceutical strategy.

Original publication

DOI

10.1146/annurev-nutr-071715-050731

Type

Journal article

Journal

Annu Rev Nutr

Publication Date

17/07/2016

Volume

36

Pages

417 - 434

Keywords

erythroferrone, erythropoiesis, hepcidin, iron, thalassemia, Animals, Down-Regulation, Erythropoiesis, Evidence-Based Medicine, Hematopoietic Stem Cells, Hepcidins, Homeostasis, Humans, Iron, Ligands, Models, Biological, Peptide Hormones, Up-Regulation